Catalyst Event
Astrazeneca PLC (AZN) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
6/2/2026, 12:00:00 AM
Presented positive final results from the Phase III SERENA-6 trial for camizestrant in breast cancer at the ASCO 2026 Annual Meeting, showing a 37% reduction in risk of second disease progression or death. High importance estimated due to significant clinical success in a major indication.
Korean Translation
ASCO 2026 연례회의에서 유방암 치료제 카미제스트란트(camizestrant)의 SERENA-6 3상 임상시험 최종 긍정적 결과를 발표했으며, 2차 질병 진행 또는 사망 위험을 37% 감소시킨 것으로 나타남. 주요 적응증에서의 유의미한 임상적 성공으로 인해 높은 중요도로 평가함.
Related Recent Events
Life Time Group Holdings Inc (LTH) · Earnings Release
Q2 2026 earnings release on 2026-08-04 with analyst EPS forecast of $0.43; low importance estimated due to no current market impact, expected.
8/4/2026, 12:00:00 AM
Novartis AG (NVS) · Earnings Release
Second quarter 2026 financial results for 2026-07-21; low importance estimated as the date is a routine reporting event with an expected impact of approximately 1% scheduled.
7/21/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
7/16/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
FDA action date (PDUFA) for supplemental applications for WELIREG in combination with KEYTRUDA for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) is scheduled for June 19, 2026, scheduled.
6/19/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
Quarterly dividend of $0.85 per share has an ex-dividend date of June 15, 2026, scheduled.
6/15/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Ex-dividend date for a quarterly cash dividend of $1.25 per share on 2026-06-12. The dividend was declared on May 26, 2026, and is payable on June 26, 2026. A price impact of approximately 1% is expected based on the dividend amount.
6/12/2026, 12:00:00 AM